Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BJSE:920344's EV-to-FCF is ranked worse than 76.79% of 349
companies
in the Biotechnology industry
Industry Median: 14.07
vs BJSE:920344: 45.54
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Beijing Tri Prime Gene Pharmaceutical Co (BJSE:920344) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Beijing Tri Prime Gene Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Beijing Tri Prime Gene Pharmaceutical Co's share price for today is ¥18.55.
Beijing Tri Prime Gene Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.150.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Beijing Tri Prime Gene Pharmaceutical Co EV-to-FCF Related Terms
Beijing Tri Prime Gene Pharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Tri Prime Gene Pharmaceutical Co EV-to-FCF Chart
Beijing Tri Prime Gene Pharmaceutical Co Annual Data
BJSE:920344 vs VRTX, REGN, RVMD: EV-to-FCF Comparison
For the Biotechnology subindustry, Beijing Tri Prime Gene Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Tri Prime Gene Pharmaceutical Co EV-to-FCF vs Biotechnology Industry
Beijing Tri Prime Gene Pharmaceutical Co's current Enterprise Value is ¥2,652.1 Mil.
Beijing Tri Prime Gene Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥56.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Tri Prime Gene Pharmaceutical Co (BJSE:920344) has a EV-to-FCF of 46.79 as of Aug. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Beijing Tri Prime Gene Pharmaceutical Co and its competitors. According to the industry distribution chart, Beijing Tri Prime Gene Pharmaceutical Co ranks #268 out of 349 companies in the Biotechnology industry, placing it in the top 76.8%.
Is Beijing Tri Prime Gene Pharmaceutical Co's EV-to-FCF too high?
Beijing Tri Prime Gene Pharmaceutical Co's current EV-to-FCF is 46.79. The Biotechnology industry median EV-to-FCF is 14.07. Beijing Tri Prime Gene Pharmaceutical Co's value of 46.79 is 232.6% above this industry median. Based on the distribution chart, Beijing Tri Prime Gene Pharmaceutical Co ranks #268 out of 349 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Beijing Tri Prime Gene Pharmaceutical Co has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Tri Prime Gene Pharmaceutical Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Beijing Tri Prime Gene Pharmaceutical Co ranks #268 out of 349 companies for EV-to-FCF. This places Beijing Tri Prime Gene Pharmaceutical Co in the lower half of its industry. The industry median EV-to-FCF is 14.07. Beijing Tri Prime Gene Pharmaceutical Co's value of 46.79 is 232.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.07, based on 349 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Tri Prime Gene Pharmaceutical Co's current EV-to-FCF of 46.79 is 232.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Beijing Tri Prime Gene Pharmaceutical Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Tri Prime Gene Pharmaceutical Co's current EV-to-FCF is 46.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Tri Prime Gene Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Tri Prime Gene Pharmaceutical Co (BJSE:920344) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥25.94, compared to a current price of ¥18.55 — trading 28.5% below its estimated fair value. The current EV-to-FCF is 46.79 and 232.6% above the Biotechnology industry median of 14.07. Beijing Tri Prime Gene Pharmaceutical Co's overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Beijing Tri Prime Gene Pharmaceutical Co (BJSE:920344), the current EV-to-FCF is 46.79 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Tri Prime Gene Pharmaceutical Co (BJSE:920344) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Tri Prime Gene Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥18.55 is trading 28.5% below its estimated GF Value™ of ¥25.94.
GuruFocus considers Beijing Tri Prime Gene Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for BJSE:920344:
EV-to-FCF: 46.79
GF Value™: ¥25.94 vs. price of ¥18.55 (28.5% below fair value)
Industry Position: 232.6% above the Biotechnology median (#268 of 349)
No single metric tells the full story. See the BJSE:920344 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Tri Prime Gene Pharmaceutical Co Ltd is mainly engaged in the research, development, production, and sales of medical biotechnology products, including genetic engineering drugs, genetic engineering vaccines, and diagnostic reagents, and is engaged in related technical trade and technical consulting services. Its product line comprises Yundex Spray, Yundex Eye Drops, Yundexol Powder Injection, and Yundexol Water Injection.
77GF Score
Get the complete analysis for BJSE:920344
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920344 has been successfully added to your 
